New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients
Oak Ridge, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the presentation of data from a Phase I National Institute of Health (NIH) sponsored randomized control trial (RCT) from two Veterans Affairs Medical Centers (Boston , Minneapolis), validating treatment decisions guided by the Company’s BVA-100® diagnostic blood test benefitted patients with acute decompensated heart failure (ADHF). Data were presented at the American Heart Association Scientific Sessions 2023 at the Pennsylvania Convention Center in Philadelphia, PA on November 11, 2023.
- Data were presented at the American Heart Association Scientific Sessions 2023 at the Pennsylvania Convention Center in Philadelphia, PA on November 11, 2023.
- Data showed that on average 7 out of 10 ADHF patients are not being accurately diagnosed.
- Clinical assessments of volume status and anemia were collected for all patients prior to BVA measurement at hospital admission and post-discharge.
- Patients in the BVA-guided arm received treatment informed by the BVA test results, in the blinded arm volume was only assessed using clinical tools and biomarkers absent the BVA results.